- -
-
Compounds of formula (I) useful as tyrosine kinase 2 (Tyk2) inhibitors, pharmaceutical compositions containing these compounds, methods of using the pharmaceutical compositions in the treatment of various disorders related to the regulation of Tyk2 activi
- -
-
Paragraph 0196; 0235-0237
(2022/01/12)
-
- Compound used as CDK7 kinase inhibitor and application thereof
-
The invention relates to a compound used as a CDK7 kinase inhibitor and application thereof. Specifically, the compound disclosed by the invention has a structure shown as a formula I, and the definitions of all groups and substituents are as described in the specification. The compounds of the present invention are useful as inhibitors of cyclin-dependent kinase 7 (CDK7) for the treatment or prevention of proliferative diseases such as cancer, especially for modulating and treating diseases associated with abnormal activity of cyclin-dependent kinase 7 (CDK7).
- -
-
-
- Synthesis of 2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide and 3-oxo-3,4-dihydrobenzo[b][1,4]oxazine-8-carboxamide derivatives as PARP1 inhibitors
-
Poly(ADP-ribose) polymerase 1 (PARP1), a widely explored anticancer drug target, plays an important role in single-strand DNA break repair processes. High-throughput virtual screening (HTVS) of a Maybridge small molecule library using the PARP1-benzimidazole-4-carboxamide co-crystal structure and pharmacophore model led to the identification of eleven compounds. These compounds were evaluated using recombinant PARP1 enzyme assay that resulted in the acquisition of three PARP1 inhibitors: 3 (IC50 = 12 μM), 4 (IC50 = 5.8 μM), and 10 (IC50 = 0.88 μM). Compound 4 (2,3-dihydro-1,4-benzodioxine-5-carboxamide) was selected as a lead and was subjected to further chemical modifications, involving analogue synthesis and scaffold hopping. These efforts led to the identification of (Z)-2-(4-hydroxybenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (49, IC50 = 0.082 μM) as the most potent inhibitor of PARP1 from the series.
- Shao, Xuwei,Pak, Steven,Velagapudi, Uday Kiran,Gobbooru, Shruthi,Kommaraju, Sai Shilpa,Low, Woon-Kai,Subramaniam, Gopal,Pathak, Sanjai Kumar,Talele, Tanaji T.
-
-
- As neuroprotective agents of pharmaceutical compounds
-
The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.
- -
-
Paragraph 0100; 0101; 0102-0104
(2019/06/26)
-
- Pharmaceutical composition for use in preventing or treating poly(ADP-ribose)polymerase-1 related diseases containing the same as an active ingredient
-
The present invention relates to a novel compound, a method for manufacturing the same, and a pharmaceutical composition for preventing or treating poly(ADP-ribose)polymerase-1 (PARP-1) related diseases containing the compound as an active ingredient. The novel PARP-1 inhibitory compound according to the present invention exhibits an excellent PARP-1 inhibitory effect at a concentration of nanomol unit and further exhibits an excellent cytoprotective effect (cell death inhibitory effect) on ophthalmic diseases or disorders, especially on retinal diseases. The composition containing the compound as an active ingredient is useful as a composition for preventing or treating PARP-1 related diseases, for example, ophthalmic diseases or disorders.(AA) Example 37(BB) Example 39COPYRIGHT KIPO 2018
- -
-
Paragraph 0326; 0328-0330
(2018/06/29)
-
- Benzo wicked zuozuo apperception compound and its preparation and use
-
The invention provides a benzoxazole compound. The structure of the benzoxazole compound is shown in the formula (I), wherein R1, R2, R3 and R4 are hydrogen, C1-C5 alkyl, benzyl, aryl or hetero aryl. The preparation method of the benzoxazole compound is carried out according to the following reaction route. Compared with the prior art, the benzoxazole compound has the benefits that the Sortase A protease of bacteroid is used as a target spot, a similar structure of a Sortase A substrate is constructed through the action mechanism of the known Sortase A and the cell wall of a host cell, and new compounds with benzoxazole and mother nucleus are synthesized; the new compounds carry out the test screening of Sortase A activity inhibition so as to try to find candidate compounds for effectively inhibiting staphylococcus aureus infection.
- -
-
Paragraph 0043-0045
(2017/10/27)
-
- High-selectivity direct diazotization method for inducing phenolic ester and oxynitride through metal coordination
-
The invention discloses a high-selectivity direct diazotization method for inducing phenolic ester and oxynitride through metal coordination. The method comprises the following steps: adding metal salt into a solution of a phenolic ester compound, so as to enable the metal salt to be coordinated with phenolic ester and to activate a carbon-carbon bond aligned with a phenolic hydroxyl group. Activated phenolic ester can directly react with the oxynitride at low temperature or normal temperature, so as to form heavy oxynitride and separate out solid diazonium salt, and a required product can be obtained only through a simple liquid-solid separation method. Reaction liquid can be recycled after reactants are replenished and the acidity of the solution is adjusted. The method avoids two reaction steps that are nitration and reduction to form amino compound in the existing method, and the product can be directly obtained through one step. The method not only solves the problem of diazotization of a major type of non-active aromatic compounds, but also can utilize various oxynitride waste gas and even utilize sulfur-containing oxide waste gas as a reactant, changes waste materials into things of value, and is applied to the treatment of industrial waste gas.
- -
-
Paragraph 0027; 0030; 0031; 0045
(2017/07/19)
-
- Synthesis, biological evaluation and molecular docking of 2-phenyl-benzo[d]oxazole-7-carboxamide derivatives as potential Staphylococcus aureus Sortase A inhibitors
-
A series of novel 2-phenyl-benzo[d]oxazole-7-carboxamide derivatives were designed, synthesized and evaluated for their in vitro inhibitory activities against Staphylococcus aureus Sortase A with known Sortase A inhibitor pHMB as positive compound (IC50?=?130?μM). Most compounds exhibited excellent inhibitory activity (IC50?=?19.8–184.2?μM). Structure–activity relationship studies demonstrated that substitution at 7-position and 2-position of benzoxazole had great influence on the activities. Specifically, the substituent at 7-position is indispensable for inhibitory activity. The molecular docking studies revealed the i-butyl amide group went towards the β6/β7 loop-β8 substructure of the protein and the benzoxazole core lied in a hydrophobic pocket composed of Ala118, Val166, Val168, Val169 and Ile182, shaping the whole molecule into a L-shape mode to be recognized by Sortase A.
- Zhang, Yong,Bao, Jian,Deng, Xin-Xian,He, Wan,Fan, Jia-Jun,Jiang, Fa-Qin,Fu, Lei
-
p. 4081 - 4085
(2016/08/01)
-
- ANTI-MALIGNANT TUMOR AGENT COMPOSITION
-
To provide a satisfactory anticancer agent composition suppressing the growth of cancer (malignant tumor) reliably and hardly causing side effects, the present invention is directed to an anticancer agent composition including the following agents as active ingredient; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.
- -
-
Paragraph 0115
(2016/01/25)
-
- Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists
-
N-Benzyl substitution of phenethylamine 5-HT2A receptor agonists has dramatic effects on binding affinity, receptor selectivity and agonist activity. In this paper we examine how affinity for the 5-HT2A/2C receptors are influenced by N-benzyl substitution of 4-bromo-2,5-dimethoxyphenethylamine derivatives. Special attention is given to the 2′ and 3′-position of the N-benzyl as such compounds are known to be very potent. We found that substitutions in these positions are generally well tolerated. The 2′-position was further examined using a range of substituents to probe the hydrogen bonding requirements for optimal affinity and selectivity, and it was found that small changes in the ligands in this area had a profound effect on their affinities. Furthermore, two ligands that lack a 2′-benzyl substituent were also found to have high affinity contradicting previous held notions. Several high-affinity ligands were identified and assayed for functional activity at the 5-HT2A and 5-HT2C receptor, and they were generally found to be less efficacious agonists than previously reported N-benzyl phenethylamines.
- Hansen, Martin,Jacobsen, Stine Engesgaard,Plunkett, Shane,Liebscher, Gudrun Eckhard,McCorvy, John D.,Br?uner-Osborne, Hans,Kristensen, Jesper Langgaard
-
supporting information
p. 3933 - 3937
(2015/01/30)
-
- Coordination-mediated radical nitration of methyl salicylate by ferric nitrate
-
Nitration of methyl salicylate was performed by ferric nitrate in refluxing ethyl acetate solution. A coordination-mediated radical nitration process was proposed based on the results of electronic absorption spectra, cyclic voltammetry and electrospray ionization mass spectra. It was the coordination of methyl salicylate with ferric nitrate that promoted the splitting of N-O bonds of nitrate group in ferric nitrate and resulted in the formation of nitro radicals, oxygen radicals and complex radicals. The nitro radicals reacted with methyl salicylate or its complexes with iron to give a series of nitration products and Fe(II) ions. Meanwhile, oxygen radicals hydrolyzed to hydroxide which precipitated free ferric ions to isolate solid ferric oxides.
- Liu, Yanzhu,Zu, Mingming,Zou, Xiuxin,Zheng, Qing,Li, Xia,Zhou, Xuezhen,Tang, Qun,Zhang, Shihan,Zhang, Ling,Li, Yongxiu
-
p. 241 - 246
(2014/03/21)
-
- Enantioselective bromolactonization of conjugated (2)-enynes
-
"Chemical equation presented" A catalytic enantioselective syn-1,4-bromolactonization of conjugated (Z)-enynes was reported. Diastereomeric ratios >20:1 and up to 99% enantiomeric excesses were observed. Di-, tri-, and tetra-substituted bromoallenes were prepared together with lactone heterocycles efficiently and stereoselectively. Preliminary investigations suggest that the chiral catalyst may serve as a bifunctional reagent by interacting with both a carboxylic acid nucleophile and NBS electrophile.
- Zhang, Wei,Zheng, Suqing,Liu, Na,Werness, Jenny B.,Guzei, Llia A.,Tang, Weiplng
-
supporting information; experimental part
p. 3664 - 3665
(2010/05/15)
-
- Synthesis, structural investigations, hydrogen-deuterium exchange studies, and molecular modeling of conformationally stablilized aromatic oligoamides
-
Biasing the conformational preferences of aromatic oligoamides by internally placing intramolecular hydrogen bonds has led to a series of stably folded molecular strands. This article presents the results from extensive solid-state, solution, and computational studies on these folding oligomers. Depending on its backbone length, an oligoamide adopts a crescent or helical conformation. Surprisingly, despite the highly repetitive nature of the backbone, the internally placed, otherwise very similar intramolecular hydrogen bonds showed significantly different stabilities as demonstrated by hydrogen-deuterium exchange data. It was also observed that the hydrogen-bonding strength can be tuned by adjusting the substituents attached to the exterior of the aromatic backbones. Examining the amide hydrogen-deuterium exchange rates of trimers revealed that a six-membered hydrogen bond nearing the ester end is the weakest among all the four intramolecular hydrogen bonds of a molecule. This observation was verified by ab initio quantum mechanical calculations at the level of B3LYP/6-31G. Such a "weak point" creates the "battle of the bulge" where backbone twisting is centered, which is consistently observed in the solid-state structures of the four trimer molecules studied. In the solid state, the oligomers assemble into interesting one-dimensional structures. A pronounced columnar packing of short oligomers (i.e., dimers, trimers, and tetramer) and channel-like, potentially ion-conducting stacks of longer oligomers (i.e., tetramer, pentamer, and hexamer) were observed.
- Yan, Yan,Qin, Bo,Ren, Changliang,Yip, Yeow Kwan,Ye, Ruijuan,Zeng, Huaqiang,Chen, Xiuying,Su, Haibin,Zhang, Dawei
-
supporting information; experimental part
p. 5869 - 5879
(2010/07/13)
-
- DIHYDROOROTATE DEHYDROGENASE INHIBITORS
-
The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.
- -
-
Page/Page column 83
(2010/11/03)
-
- Discovery of inhibitors of aberrant gene transcription from libraries ofdna binding molecules: Inhibition of LEF-1-mediated gene transcription and oncogenic transformation
-
The screening of a >9000 compound library of synthetic DNA binding molecules for selective binding to the consensus sequence of the transcription factor LEF-1 followed by assessment of the candidate compounds in a series of assays that characterized functional activity (disruption of DNA-LEF-1 binding) at the intended target and site (inhibition of intracellular LEF-1-mediated gene transcription) resulting in a desired phenotypic cellular change (inhibit LEF-1-driven cell transformation) provided two lead compounds: lefmycin-1 and lefmycin-2. The sequence of screens defining the approach assures that activity in the final functional assay may be directly related to the inhibition of gene transcription and DNA binding properties of the identified molecules. Central to the implementation of this generalized approach to the discovery of DNA binding small molecule inhibitors of gene transcription was (1) the use of a technically nondemanding fluorescent intercalator displacement (FID) assay for initial assessment of the DNA binding affinity and selectivity of a library of compounds for any sequence of interest, and (2) the technology usedto prepare a sufficiently large library of DNA binding compounds.
- Stover, James S.,Shi, Jin,Jin, Wei,Vogt, Peter K.,Boger, Dale L.
-
supporting information; experimental part
p. 3342 - 3348
(2009/07/30)
-
- Helical organization in foldable aromatic oligoamides by a continuous hydrogen-bonding network
-
Introduction of a continuous internal hydrogen-bonding network suppressed the conformational flexibility of a series of oligoaromatic foldamers with a lengthened backbone. The helical ordering over up to six aromatic repeating units was established in solution by a 2D NOESY study and in the solid state by an X-ray diffraction method. Computational molecular modeling further corroborates the experimentally observed helical propagation in this class of foldable molecular strands.
- Yan, Yan,Qin, Bo,Shu, Yingying,Chen, Xiuying,Yip, Yeow Kwan,Zhang, Dawei,Su, Haibin,Zeng, Huaqiang
-
supporting information; experimental part
p. 1201 - 1204
(2009/08/07)
-
- Benzene Sulfonamide Thiazole and Oxazole Compounds
-
The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
- -
-
Page/Page column 84
(2009/12/23)
-
- Synthesis of platensimycin analogues and their antibiotic potency
-
Platensimycin is a natural product isolated from various strains of Streptomyces platensis which exhibits antimicrobial activity against Gram positive bacteria, including vancomycin- and linezolide-resistant species. Analogues of platensimycin were synthesized from 3-aminobenzoic acid or other aniline derivatives and several alkyl- and aryl-carboxylic acids. The resulting compounds were tested in an agar diffusion assay against several bacteria and fungi.
- Krauss, Juergen,Knorr, Veronika,Manhardt, Vera,Scheffels, Stefanie,Bracher, Franz
-
experimental part
p. 386 - 392
(2009/04/16)
-
- Crystallographic evidence of an unusual, pentagon-shaped folding pattern in a circular aromatic pentamer
-
(Figure Presented) Introduction of a continuous hydrogen-bonding network suppressed the conformational flexibility of an oligomeric backbone. Cyclization of a rigidified, suitably sized oligomer led to a circular aromatic pentamer. Its crystal structure d
- Qin, Bo,Chen, Xiuying,Fang, Xiao,Shu, Yingying,Yip, Yeow Kwan,Yan, Yan,Pan, Siyan,Ong, Wei Qiang,Ren, Changliang,Su, Haibin,Zeng, Huaqiang
-
supporting information; experimental part
p. 5127 - 5130
(2009/05/30)
-
- Intramolecular hydrogen bonding of o-hydroxyesters and related compounds evaluated by deuterium isotope effects on 13C chemical shifts and principal component analysis
-
o-Hydroxyaromatic esters, β-hydroxyketoesters, Meldrums acids, other o-hydroxyesters and a few o-hydroxyacid anhydrides are investigated by deuterium isotope effects on 13C chemical shifts, xΔC(OD). Especially the ester carbons show unusual deuterium isotope effects. A principal component analysis based on bond lengths and distances around the hydrogen bond six-membered ring make it possible to predict isotope effects. The ratio nΔC{double bond, long}O(OD)/2ΔC(OD) can be used to predict the extent of transmission via the hydrogen bond. Furthermore, deuterium isotope effects can be used to gauge possible tautomerism.
- Hansen, Poul Erik,Kamounah, Fadhil S.,Ullah, Saif
-
p. 300 - 307
(2008/03/13)
-
- 3,4-DIHYDROBENZOXAZINE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VRI) ACTIVITY
-
A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be s
- -
-
Page/Page column 13
(2010/11/27)
-
- CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY
-
To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain
- -
-
Page/Page column 31
(2010/11/28)
-
- THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
-
Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).
- -
-
Page/Page column 144
(2010/02/12)
-
- ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
-
Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
- -
-
Page/Page column 147
(2010/02/13)
-
- Esterification-nitration of ortho-hydroxyphenyl carboxylic acids and benzole acids with cerium(IV) ammonium nitrate (CAN)
-
A convenient and useful esterification was realized, and this reaction proceeded without a dehydrating reagent or water removal equipment. A series of ortho -hydroxyphenyl carboxylic acids and benzoic acids were transformed to their corresponding methyl esters under CAN/CH3OH reaction conditions. Whereas in an aprotic solvent, acetonitrile, sp3-C tethered ortho-hydroxyphenyl carboxylic acids undergo simultaneous o,p-dinitration and intramolecular esterification reactions in good yields. Also, 2-((1E)-2-nitrovinyl)-4-nitro-phenol (3e) showed selective cytotoxicities to ward MCF-7, HEP G2, and HEP 3B cell lines with IQovalues of 23.50, 7.33, and7.59ug/mL,respectively.
- Pan, Wen-Bin,Wei, Li-Mei,Wei, Li-Lan,Wu, Chin-Chung,Wu, Yang-Chang
-
p. 173 - 180
(2007/10/03)
-
- THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS
-
Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).
- -
-
-
- 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
-
There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
- -
-
-
- NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY
-
A compound of the formula (I): wherein Z4, Z5 and Z9 each is independently carbon atom or nitrogen atom; Y is hydroxy, mercapto or amino; RA is a group of the formula: (wherein C ring is nitrogen-containing heteroaryl) has an inhibitory activity against integrase.
- -
-
Page 143; 144
(2008/06/13)
-
- FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS
-
The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.
- -
-
-
- 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
-
There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
- -
-
-
- PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES
-
The present invention relates to phthalimide carboxylic acid derivatives of formula (I), methods for their preparation, pharmaceutical compositions containing them and their use in medicine, specifically in the treatment of cancer. (I), wherein X is O or S; R1 is a phthalimide carboxylic acid group of formula (II). R is hydrogen, C1-C6 alkyl, aryl or C1-C3 alkylaryl and R2, R3 and R4 represent various substituents.
- -
-
Page/Page column 66
(2008/06/13)
-
- 3-(benzofuran-7-yl)-6-haloalkyluracils
-
Herbicidal 3-(benzofuran-7-yl)-6-haloalkyluracils of the formula STR1 in which M is fluoroalkyl (C1-6); D is hydrogen, alkyl (C1-6), or alkoxy(C1-6)-carbonyl; E is hydrogen or alkyl (C1-6), or D and E taken together are --CH2 CH2 --; R is hydrogen, amino, alkyl (C1-6), 2-alkenyl (C3-6), 2-alkynyl (C3-6), alkoxy(C1-6)methyl, benzyl, amino, fluoroalkyl (C1-6), alkoxy (C1-6)-carbonylmethyl; or cyanoalkyl (C1-6) having preferably one cyano group; X is hydrogen, fluorine, chlorine, bromine, cyano, alkyl(C1-6), haloalkyl(C1-6), haloalkoxy(C1-6), or alkoxy(C1-6); Y is hydrogen, alkyl (C1-6), fluorine, chlorine, or bromine; and Z is CH2, C=O, C=S, --CH(OH)--, --CH2 CH2 --, --CH=CH--, --(C=O)CH2 --; or C=N--O--R' wherein R' is alkyl(C1-6).
- -
-
-